Open AccessFactors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis
Author(s) -
M.H. Otten,
Femke H. M. Prince,
Wineke Armbrust,
R. ten Cate,
E.P.A.H. Hoppenreijs,
Marinka Twilt,
Y. Koopman-Keemink,
Simone Gorter,
Koert M. Dolman,
Joost F. Swart,
J. Merlijn van den Berg,
Nico Wulffraat,
Marion A. J. van Rossum,
Lisette W. A. van SuijlekomSmit
Publication year - 2011
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2011.1671
Subject(s) - etanercept , medicine , discontinuation , arthritis , methotrexate , prospective cohort study , odds ratio , rheumatoid arthritis
Since the introduction of biologic therapies, the pharmacological treatment approach for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive disease as a realistic goal.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom